CARB-X is funding French biotech Mutabilis to develop a new class of antibacterials to treat infections caused by carbapenem-resistant Enterobacterales

CARB-X is awarding Mutabilis, a biopharmaceutical firm based in Romainville, France, up to US$6.4 million to develop a new drug to treat infections caused by Carbapenem-resistant Enterobacterales (CRE) bacteria. CRE has been dubbed the ‘nightmare bacteria’ by health officials because they cause deadly infections – often in healthcare settings – that cannot be effectively treated with existing antibiotics. Under the award agreement, Mutabilis will be eligible for an additional $5.8 million in further funding if certain project milestones are met, subject to available funds.

Smart Innovations   Back